Table 1.
HRQL | Unadjusted | Model 1† | Model 2‡ | ||||||
---|---|---|---|---|---|---|---|---|---|
B | 95% CI | p value | B | 95% CI | p value | B | 95% CI | p value | |
Overall | |||||||||
0–5 years | Ref | Ref | Ref | ||||||
6–12 years | 1.21 | 0.61–1.82 | <0.001 | 0.71 | 0.18–1.23 | 0.01 | 0.60 | 0.05–1.16 | 0.04 |
FA | |||||||||
0–5 years | Ref | Ref | Ref | ||||||
6–12 years | 1.51 | 0.93–2.09 | <0.01 | 1.06 | 0.52–1.61 | <0.001 | 1.09 | 0.50–1.67 | 0.001 |
EI | |||||||||
0–5 years | Ref | Ref | Ref | ||||||
6–12 years | 1.27 | 0.67–1.88 | <0.001 | 0.76 | 0.21–1.31 | 0.008 | 0.66 | 0.07–1.24 | 0.03 |
SDL | |||||||||
0–5 years | Ref | Ref | Ref | ||||||
6–12 years | 0.94 | 0.18–1.69 | 0.02 | 0.39 | − 0.35–1.13 | 0.30 | 0.20 | − 0.58–0.97 | 0.61 |
95% CI 95th percent confidence interval, EAI epinephrine autoinjector, EI emotional impact, FA food anxiety, HRQL health-related quality of life, SDL social and dietary limitations
†Adjusted for symptom severity, EAI prescription and number of concomitant allergic diseases
‡Adjusted for symptom severity, EAI prescription, number of concomitant allergic diseases and region